Bausch + Lomb BLCO Pharmaceuticals — Operating Income (Loss)

Other segment segments

Similar metrics at other companies

BAXPharmaceuticals — Segment operating income

$46M-27.0%

VRTXPharmaceuticals — income (loss)

$1.03B+59.6%

TMOLaboratory Products and Biopharma Services — Operating Income (Loss)

$778M+6.4%

INCYOperating Income

$301.12M+46.8%

AMRXAffordable Medicines — Operating Income (Loss)

$120.94M+9.2%

BMRNOperating Income

$129.64M-42.1%

Questions, answered.

What is Bausch + Lomb's pharmaceuticals — operating income (loss)?

Bausch + Lomb (BLCO) reported pharmaceuticals — operating income (loss) of $66M in Q1 2026.

How has Bausch + Lomb's pharmaceuticals — operating income (loss) changed year-over-year?

Bausch + Lomb's pharmaceuticals — operating income (loss) increased by 500.0% year-over-year, from $11M to $66M.

What is the long-term trend for Bausch + Lomb's pharmaceuticals — operating income (loss)?

Over 4 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — operating income (loss) has grown at a -3.8% compound annual growth rate (CAGR), from $301M to $258M.

What does pharmaceuticals — operating income (loss) mean?

Measures the profitability of the pharmaceutical segment after deducting operating expenses from total revenues, excluding interest and taxes. It serves as the primary benchmark for evaluating the core operational performance and margin management of the pharmaceutical business unit.